The activation of the cGAS-STING pathway by POLE mutation likely contributes to the advantageous survival of endometrial cancer patients with POLE mutations, as the cGAS-STING pathway has been associated with anti-tumor activity through the stimulation of inflammatory genes [20, 21]. The gene discussed is STING1; the disease is neoplasm.